ARLINGTON HEIGHTS, Ill.–(BUSINESS WIRE) September 27, 2024 –GE HealthCare (Nasdaq: GEHC) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of Flyrcado (flurpiridaz F 18) injection, a first of its kind positron…Original Article
FDA Approves Flyrcado (flurpiridaz F 18) Radioactive Diagnostic for Enhanced Diagnosis of Coronary Artery Disease
